Karyopharm Therapeutics Inc Dossier - Source-backed chat

Karyopharm Therapeutics Inc

KPTINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.88

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.87Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $19.7M

Shares Outstanding 22.7M diluted

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Karyopharm Therapeutics is at a critical inflection point in 2026, driven by late-stage clinical catalysts that could dramatically expand the addressable market for its lead XPO1 inhibitor, selinexor (XPOVIO). The Phase 3 SENTRY trial in frontline myelofibrosis has already demonstrated a statistically significant spleen volume reduction (SVR35) and a promising overall survival signal. The upcoming mid-2026 topline readout of the Phase 3 XPORT-EC-042 trial in TP53 wild-type endometrial cancer represents a multi-billion dollar market opportunity with no currently approved maintenance therapies. While the company faces near-term liquidity constraints, positive clinical readouts are expected to unlock strategic partnerships, non-dilutive funding, or capital restructuring to extend its operational runway.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$13.00

Mean target$14.80

High · most bullish analyst$16.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0020%

The Phase 3 XPORT-EC-042 trial fails to show a statistically significant PFS benefit in endometrial cancer, or the safety profile is deemed unfavorable due to tolerability issues. FDA feedback on the SENTRY myelofibrosis data requires additional clinical trials before filing, delaying potential approval. The lack of positive catalysts prevents the company from raising capital on favorable terms, leading to severe dilution or restructuring under liquidity distress.

Base CaseCentral scenario

$12.0050%

The Phase 3 XPORT-EC-042 trial meets its primary endpoint in the TP53 wild-type endometrial cancer population, and the company successfully files sNDAs for both endometrial cancer and myelofibrosis. Commercial execution of XPOVIO in its current multiple myeloma indications remains steady, meeting the 2026 revenue guidance of $130M to $150M. The company successfully secures additional financing or a regional partnership to extend its cash runway past late 2026.

Bull CaseUpside scenario

$16.0030%

The Phase 3 XPORT-EC-042 trial in endometrial cancer delivers highly positive topline results, confirming the strong PFS benefit observed in the SIENDO subgroup analysis. The FDA grants priority review for both the endometrial cancer maintenance and frontline myelofibrosis indications, leading to approvals in 2027. Selinexor establishes itself as the standard of care in these high-unmet-need markets, driving peak annual revenues toward $1 billion and securing a lucrative global commercialization partnership.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pivotal Phase 3 SENTRY trial in myelofibrosis met its co-primary endpoint, showing a rapid and near-doubling of patients achieving SVR35 at week 24 (50% vs. 28%) with a promising overall survival hazard ratio of 0.43.
Upcoming mid-2026 topline readout for Phase 3 XPORT-EC-042 in TP53 wild-type endometrial cancer targets a large, unserved maintenance market estimated at over $2 billion in the U.S. alone.
Established commercial infrastructure in the U.S. and regulatory approvals in over 50 countries provide a solid foundation to support rapid launch execution in new indications.

Key Investment Risks

Significant liquidity risk, with current cash and equivalents of $91.2 million expected to fund operations only into late Q3 2026, necessitating near-term capital raises or strategic partnerships.
High reliance on a single active pharmaceutical ingredient, selinexor (XPOVIO), making the company's valuation highly sensitive to clinical, regulatory, and commercial outcomes for this single asset.
Intense competition in the oncology space, particularly in multiple myeloma, which has pressured underlying demand for XPOVIO.

Thesis Invalidation Triggers

Failure of the Phase 3 XPORT-EC-042 trial to meet its primary endpoint of progression-free survival (PFS) in TP53 wild-type endometrial cancer.
Inability to secure additional financing, licensing revenue, or strategic partnerships by the end of Q3 2026, resulting in a severe cash crunch.
Regulatory refusal by the FDA to accept sNDA filings for selinexor in myelofibrosis or endometrial cancer without further clinical trials.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.